Although receptor-targeting antibodies are gaining traction in cancer research, our results suggest that IFNGR targeting would be ineffective in inhibiting IFN-γ-induced signaling, given that these cells do not have adequate IFNGR levels. This evidence concerns the gene IFNGR1 and cancer.